Virology & Mycology
ISSN: 2161-0517
OPEN ACCESS Freely available online
Short Communication

Antiretroviral Activity of Ibalizumab for the Treatment of HIV-1 Infection

Mike Scott*

Department of Pharmacy, University of Patras, Patras, Greece

DESCRIPTION

AIDS and the Human Immunodeficiency Virus (HIV) are major public health concerns for nations around the world, including the United States. The prognosis of people with HIV infection has greatly improved with the introduction of Anti-Retroviral Therapy (ART). Despite the benefits of contemporary ART, there are rising worries about resistance to treatments that are accessible. Multidrug-Resistant (MDR) strains are thought to be present in about 25,000 HIV patients in the United States, with 12,000 of these patients in particular urgently in need of new treatment alternatives because their previous regimens had failed [1]. Accordingly, the creation of novel drugs with distinctive mechanisms of action and means of delivery would be advantageous for patients with MDR HIV, which is defined as phenotypic or genotypic resistance to at least one treatment in three classes of antiretroviral medicines. In comparison to other antiretroviral drugs, the use of a Monoclonal Antibodies (MAb) for HIV therapy has a number of advantages, including a distinct mode of action, the capacity to increase Clusters of differentiation 4 (CD4) T cell numbers, a low risk of toxicities and a minimal ability to develop acquired resistance [2]. The first intravenous Monoclonal Antibodies (MAb) created for the therapy of HIV-1 infection in more than ten years is ibalizumab-uiyk (Trogarzo [TaiMed Biologics], also known as Ibalizumab).

Ibalizumab was approved by the U.S. Food and Drug Administration (FDA) approved the use of alternative ARTs in combination with MDR HIV-1 treatment for people who have received a lot of treatment and are failing their current regimen [3].

Pharmacology

HIV's glycoprotein 120 (gp120) and glycoprotein 41 (gp41) domains make up the trimeric envelope glycoprotein. V1 through V5 are the 5 variable loops that make up the gp120 domain. The V1, V2 and V3 loops are situated close to one another and support the trimer's apex. The V3 loop serves as a significant co receptor binding site and is situated below the V1 and V2 loops. The gp120 domain's V4 and V5 loops are situated outside and extend outward. HIV envelope gp120 interacts with CD4 T cell extracellular domain 1 to start the viral entrance process [4,5].

Mechanism of action

Ibalizumab, a recombinant humanized Immunoglobulin (Ig) G4 MAb produced from mouse MAb 5A8, blocks HIV entrance into CD4 T cells by a new method. At the amino acid residues L96, P121, P122 and Q163, Ibalizumab interacts to the CD4 T cell extracellular domain 2. Furthermore, this substance binds to the amino acid positions E77 and S79 on domain 1. These amino acid residues are situated on the surface opposing the region where gp120 and the major histocompatibility complex II (MHC-II) molecule bind on domain 1 of the human CD4 protein [6]. The V1 and V2 loops normally shift into position to reveal the V3 when the HIV envelope gp120 attaches to CD4 T cell extracellular domain 1. Ibalizumab's binding mechanism causes steric hindrance, which stops these conformational changes in the CD4 T cell and HIV envelope gp120 complex. This then inhibits the rearrangement of the gp41 domain and the interaction of gp120 with the CXCR4 and CCR5 co receptors *via* the V3 loop, which hinders viral fusion and entrance into the CD4 T cell. Ibalizumab has been categorized as a parenteral CD4-directed post attachment inhibitor as a result of its potent anti-CXCR4 and CCR5-tropic activity [7].

Dosage, preparation and administration

The FDA has approved ibalizumab for intravenous infusion. It comes in single-dose vials that hold a sterile solution that is clear to slightly opalescent and ranges in color from colorless to slightly yellow. The intact vials should never be frozen (50 to 15° C), should be kept away from light and should be refrigerated (2 to 8°C). Each 1.33 ml of the single-dose vial contains 200 mg of ibalizumab. A 2,000 mg loading dosage of ibalizumab should be given first, followed by maintenance doses of 800 mg every 14 days. Ibalizumab does not require a dose change when taken with other drugs, including antiretroviral. Ibalizumab should be diluted in a 250 ml bag of 0.9% sodium chloride before being administered as directed. If not used right away, the solution can be kept chilled for up to 24 hours or at ambient temperature (20

Correspondence to: Dr. Mike Scott, Department of Pharmacy, University of Patras, Patras, Greece, E-mail: micott@cc.uoa.gr

Received: 24-May-2023, Manuscript No. VMID-23-24366; **Editor assigned:** 26-May-2023, Pre QC No. VMID-23-24366 (PQ); **Reviewed:** 09-Jun-2023, QC No. VMID-23-24366; **Revised:** 16-Jun-2023, Manuscript No. VMID-23-24366 (R); **Published:** 23-Jun-2023, DOI: 10.35248/2161-0517.23.12.259

Citation: Scott M (2023) Antiretroviral Activity of Ibalizumab for the Treatment of HIV-1 Infection. Virol Myco. 12:259.

to 25°C) for up to 4 hours. The solution needs to be maintained at room temperature for at least 30 minutes before infusion after being taken out of the refrigerator. Ibalizumab must never be given as an intravenous push or bolus [8]. Patients should be observed for 1 hour after receiving the loading dosage, which should be administered over at least 30 minutes. Maintenance dosage infusions can be provided over a minimum of 15 min and the patient monitoring period can be shortened to 15 min after administration if no infusion-related side events happen. The intravenous line should be flushed with 30 ml of 0.9% sodium chloride after injection. The patient should get another loading dosage right away if an ibalizumab maintenance dose is missed by three days or longer after the original dosing day. Following then, maintenance doses can be resumed every 14 days [9].

CONCLUSION

Recombinant humanized monoclonal antibody Ibilizumab has emerged as a cutting-edge treatment for HIV-1 infection. It binds to the amino acid residues L96, P121, P122 and Q163 and interacts with the amino acid sites E77 and S79 on domain 1 to prevent HIV entry into CD4 T cells in a novel manner. It is given intravenously in a single dose. Ibalizumab 200 mg is contained in each 1.33 ml of the single-dose vial. Ibalizumab should be administered in two doses: a loading dose of 2,000 mg and a maintenance dose of 800 mg for every 14 days.

REFERENCES

1. Iacob SA, Iacob DG. Ibalizumab targeting CD4 receptors, an emerging molecule in HIV therapy. Front Microbiol. 2017;8:2323.
2. Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, et al. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N Engl J Med. 2018;379(7):645-654.
3. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol. 2008;9(6):423-430.
4. Nakane S, Iwamoto A, Matsuda Z. The V4 and V5 variable loops of HIV-1 envelope glycoprotein are tolerant to insertion of green fluorescent protein and are useful targets for labeling. J Biol Chem. 2015;290(24):15279-15291.
5. Song R, Franco D, Kao CY, Yu F, Huang Y, Ho DD. Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J Virol. 2010;84(14): 6935-6942.
6. Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, et al. Safety, pharmacokinetics and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 2009;53(2):450-457.
7. Blumenthal R, Durell S, Viard M. HIV entry and envelope glycoprotein-mediated fusion. J Biol Chem. 2012;287(49):40841-40849.
8. Kuritzkes DR, Jacobson J, Powderly WG, Godofsky E, DeJesus E, Haas F, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis. 2004;189(2):286-291.
9. Fishwild DM, Hudson DV, Deshpande U, Kung AH. Differential effects of administration of a human anti-CD4 monoclonal antibody, HM6G, in nonhuman primates. Clin Immunol. 1999;92(2):138-152.